JanOne Inc. (JAN): Price and Financial Metrics
GET POWR RATINGS... FREE!
JAN POWR Grades
- JAN scores best on the Momentum dimension, with a Momentum rank ahead of 61.8% of US stocks.
- JAN's strongest trending metric is Sentiment; it's been moving down over the last 206 days.
- JAN's current lowest rank is in the Stability metric (where it is better than 1.21% of US stocks).
JAN Stock Summary
- JanOne Inc's market capitalization of $16,367,222 is ahead of just 4.17% of US-listed equities.
- The capital turnover (annual revenue relative to shareholder's equity) for JAN is 14.31 -- better than 97.9% of US stocks.
- JAN's price/sales ratio is 0.48; that's higher than the P/S ratio of only 9.07% of US stocks.
- Stocks that are quantitatively similar to JAN, based on their financial statements, market capitalization, and price volatility, are BDR, CSPR, HBB, BBSI, and MRC.
- Visit JAN's SEC page to see the company's official filings. To visit the company's web site, go to www.janone.com.
JAN Stock Price Chart Interactive Chart >
JAN Price/Volume Stats
| Current price | $6.62 | 52-week high | $31.83 |
| Prev. close | $6.71 | 52-week low | $2.35 |
| Day low | $6.53 | Volume | 11,583 |
| Day high | $6.62 | Avg. volume | 657,530 |
| 50-day MA | $7.93 | Dividend yield | N/A |
| 200-day MA | $6.12 | Market Cap | 15.91M |
JanOne Inc. (JAN) Company Bio
JanOne Inc. develops treatments for conditions that cause severe pain. The company, through its non-addictive pain-relieving drugs, focuses on reduction for need of opioid prescriptions to treat disease associated pain that can lead to opioid abuse. Its lead candidate JAN101 provides slow-release formulation of sodium nitrite therapeutic for treatment of peripheral artery disease (PAD). The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Latest JAN News From Around the Web
Below are the latest news stories about JanOne Inc that investors may wish to consider to help them evaluate JAN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off Thursday right with a look at the biggest pre-market stock movers that investors need to know about today. |
JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 MillionJanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is has entered into a definitive agreement to sell its legacy recycling subsidiary, ARCA Recycling, to Virland Johnson, JanOne's Chief Financial Officer, for an aggregate purchase price of approximately $25 million. The agreement follows JanOne's previously announced intent to divest its legacy businesses, allowing for a strategic corporate focus on the Company's core life science assets. |
JanOne Announces Closing of $6.0 Million Common Stock OfferingJanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering with gross proceeds of $6.0 million. The registered direct offering resulted in the sale by the company of an aggregate of 571,428 shares of common stock to certain institutional investors at a purchase price of $10.50 per share. The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the planning of clinical trials for JAN101, the company's lead drug candidate. |
JanOne Prices $6.0 Million Common Stock OfferingJanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 571,428 shares of its common stock at a price of $10.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be $6.0 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about February 2, 2021, subject to the satisfaction of customary closing conditions. |
JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery DiseaseLAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has issued its September 2020 Shareholder Letter…. |
JAN Price Returns
| 1-mo | -22.66% |
| 3-mo | -26.85% |
| 6-mo | 57.62% |
| 1-year | 168.02% |
| 3-year | 55.76% |
| 5-year | 9.42% |
| YTD | 35.38% |
| 2020 | 65.20% |
| 2019 | 34.55% |
| 2018 | -57.69% |
| 2017 | -7.14% |
| 2016 | 6.67% |
Loading social stream, please wait...